View Post

Menarini Ricerche Announces Dose Escalation Results of the Clinical Trial of MEN1611 in Breast Cancer

In Clinical Studies News by Barbara Jacoby

Source: Menarini Ricerche From: prnewswire.com Findings from B-PRECISE-01 Study Presented at the ESMO Virtual Congress 2020 Menarini Ricerche, the R&D division of the Menarini Group, today announced the results of the dose escalation part of its B-PRECISE-01 clinical trial (NCT03767335) which is evaluating MEN1611, a potent and selective phosphatidylinositol 3-kinase (PI3K) inhibitor in development for the treatment of breast cancer. …

View Post

“plasmaMATCH” Trial Matches Female Breast Cancer Patients to Precision Treatments Using Blood Test

In Clinical Studies News by Barbara Jacoby

From: technologynetworks.com A blood test that can identify a variety of mutations in advanced breast cancer can reliably match women to effective targeted treatments, early results of a major clinical trial reveal. The plasmaMATCH trial provides the strongest evidence yet that simple blood tests known as ‘liquid biopsies’ can benefit women with breast cancer by tracking their disease as it evolves and …

View Post

Similar Breast Cancer Outcomes with WBI, APBI

In Clinical Studies News by Barbara Jacoby

By: Charles Bankhead From: medpagetoday.com Similar recurrence, survival at 10 years, better tolerance, cosmesis with APBI Women with early breast cancer had similar long-term outcomes whether they had focused or whole-breast irradiation (WBI), an Italian study showed. The 10-year incidence of in-breast tumor recurrence (IBTR) was 2.5% with WBI and 3.7% with accelerated partial breast irradiation (APBI), a difference that …

View Post

Veliparib Leads to PFS Boost in Certain Breast Cancer Subsets

In Clinical Studies News by Barbara Jacoby

By: Denise Myshko From: targetedonc.com “In both subgroups, the benefit of veliparib was durable, with an increased probability of remaining progression free at 2 and 3 years compared with placebo.” When administered with carboplatin and paclitaxel,the PARP inhibitor veliparib increased progression-free survival (PFS) in patients with hormone receptor–positive breast cancer and triple-negative breast cancer (TNBC) who were positive for germline …

View Post

Junjie Li, MD, on Capecitabine in Triple-Negative Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Jeff Minerd From: medpagetoday.com Clinical trial focused exclusively on TNBC patients Current breast cancer treatment guidelines suggest that capecitabine (Xeloda) should be considered for adjuvant treatment after standard neoadjuvant therapy with taxane- and anthracycline-based chemotherapy. However, although randomized trials have evaluated capecitabine as adjuvant treatment in breast cancer overall as well as in elderly patients, none have focused solely …

View Post

Brief Quasi-Fasting Diet Boosts Breast Cancer Chemo Response

In Clinical Studies News by Barbara Jacoby

By: Mike Bassett From: medpagetoday.com A fasting mimicking diet (FMD) – a low-calorie, low-protein, plant-based, intermittent meal plan with the metabolic benefits of fasting — used over several days was a safe and effective adjunct to chemotherapy in women with early breast cancer, a randomized trial showed. FMD significantly boosted the effects of neoadjuvant chemotherapy on the radiological and pathological …

View Post

A new cancer drug might stop tumors in their tracks

In Clinical Studies News by Barbara Jacoby

By: Chris Smith From: bgr.com A new type of cancer drug has shown promising results in Phase 1 trials after preventing tumor growth in more than half of patients who did not have access to any other treatment. Called berzosertib, the drug is part of “precision medicine” therapies that target specific genes or genetic changes. Berzosertib works best when combined …

View Post

Atezolizumab Plus Chemotherapy Improves Responses in Triple-Negative Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Nichole Tucker From: targetedonc.com IMpassion031, a clinical trial of atezolizumab plus chemotherapy in patients with triple-negative breast cancer, has met its primary end point. A statistically significant and clinically meaningful improvement in pathological complete response (pCR) was achieved with the combination of the monoclonal antibody atezolizumab (Tecentriq) plus albumin-bound paclitaxel (Abraxane) and nab-paclitaxel, followed by doxorubicin when administered to …

View Post

High-Dose Chemo Most Benefits Patients With High-Risk Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Maggie L. Shaw From: ajmc.com A 20-year follow-up comprising a secondary analysis to an original study shows that high-dose chemotherapy plus hematopoietic stem cell transplant benefit patients with high-risk stage III disease with 10 or more axillary lymph nodes involved. Adjuvant high-dose chemotherapy (HDCT) with cyclophosphamide/thiotepa/carboplatin plus hematopoietic stem cell transplant (HSCT), compared with conventional-dose chemotherapy (CDCT), was shown …

View Post

Pyrotinib Combo Improves PFS in HER2+ Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Denise Myshko From: onclive.com Pyrotinib plus capecitabine achieved a better progression-free survival (PFS) than lapatinib (Tykerb) plus capecitabine in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab and chemotherapy. Results from the phase 3 PHOEBE trial (NCT03080805) with were presented as part of the 2020 ASCO Virtual Scientific Program. The median PFS was 12.5 months (95% …